NK-92/5.28.z

also known as NK-92

Developed for: acute biphenotypic leukemia · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, MLL gene rearrangement · adult acute lymphoblastic leukemia · B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) · chronic myelomonocytic leukemia · glioblastoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement
+4 more
· Hodgkins lymphoma · leukemia, myeloid, accelerated-phase · myelodysplastic syndrome with excess blasts · plasma cell myeloma
Investigated by: DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH · Georg-Speyer-Haus · German Cancer Research Center · Johann Wolfgang Goethe University Hospital · LOEWE Center Frankfurt Cancer Institute · M.D. Anderson Cancer Center
+1 more
· National Cancer Institute (NCI)

today NCT03383978 · Ph 1 NCT02727803 · Ph 2

201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT03383978	Dec 2017 → Dec 2027 expected	glioblastoma	Johann Wolfgang Goethe University Hospital	Recruiting	No outcome recorded
Phase 21 trial
Phase 2	NCT02727803	May 2016 → May 2027 expected	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), Hodgkins lymphoma, acute biphenotypic leukemia, acute myeloid leukemia with multilineage dysplasia +7	M.D. Anderson Cancer Center	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	NK-92/5.28.z	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03383978 ↗
Known as	NK-92	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02727803 ↗
Action	Deplete	“Natural killer cells may kill tumor cells” NCT02727803 ↗
Modality	Cell therapy	“personalized natural killer (NK) cell therapy” NCT02727803 ↗
Route	Other	“Intracranial application of NK-92/5.28.z” NCT03383978 ↗